Skip to content
Roboearth – Lifestyle
Author:
Harmony Biosciences
Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile
August 4, 2026
Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026
July 21, 2026